Log In
Print
BCIQ
Print
Print this Print this
 

rivipansel (GMI-1070, PF-06460031)

  Manage Alerts
Collapse Summary General Information
Company GlycoMimetics Inc.
DescriptionGlycomimetic inhibitor of E selectin (SELE; CD62E), P selectin (SELP; CD62P) and L selectin (CD62L; SELL)
Molecular Target E selectin (SELE) (CD62E) ; P selectin (SELP) (CD62P)
Mechanism of ActionPan-selectin antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationSickle cell disease
Indication DetailsPrevent or attenuate painful vaso-occlusive crisis and early death in sickle cell patients; Treat vaso-occlusive crisis (VOC) in patients with sickle cell disease
Regulatory Designation U.S. - Fast Track (Treat vaso-occlusive crisis (VOC) in patients with sickle cell disease);
U.S. - Orphan Drug (Treat vaso-occlusive crisis (VOC) in patients with sickle cell disease);
EU - Orphan Drug (Treat vaso-occlusive crisis (VOC) in patients with sickle cell disease)
Partner Pfizer Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$340.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today